Pancreatic cancer, often asymptomatic in its early stages, poses a significant challenge for timely diagnosis and treatment. By the time symptoms manifest, the disease has typically reached advanced stages, limiting the effectiveness of traditional treatments such as surgery, chemotherapy, and radiation. In this context, OncoSil emerges as a beacon of hope, offering a groundbreaking approach to pancreatic cancer treatment. Moreover, its potential as a lucrative investment opportunity further underscores its significance.